Amphista is the leading next generation TPD company, rapidly working to advance a portfolio of innovative therapeutic candidates from early stage discovery to clinical stage research and commercialization.
Amphista’s global operations and progress are guided by our mission to unlock the full therapeutic potential of TPD and make a positive difference for patients.
Our Eclipsys™ Drug Development Platform enables development of novel protein degrading therapeutics with superior levels of efficacy and broad therapeutic applicability.
The Amphista team includes leaders in biomedical research and specialists in all phases of drug development with support from leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences and Eli Lilly & Company.
About our founder
Founded by Advent Life Sciences, Amphista is built on the groundbreaking science from the laboratory of Professor Alessio Ciulli, University of Dundee, a world leader in the field of targeted protein degradation. Alessio Ciulli is Chair of Chemical and Structural Biology at the School of Life Sciences, University of Dundee, and is Founder and Director of Dundee’s new Centre for Targeted Protein Degradation (CeTPD).
Why “Amphista”?
Amphista is named for a mythical twin-headed being from Greek mythology called Amphisbaena that was said to possess many health-giving properties; this mythical creature evokes the bi-functional nature of Amphista’s novel molecules.
In ancient times, Amphisbaena played many roles in healthcare, from promoting fertility to “curing” ailments ranging from the common cold to arthritis.
Taking a somewhat more scientific approach, Amphista is building on this same spirit to develop advanced TPD therapies able to address a wide range of needs in global health.
